A scientific revolution is underway as researchers push to bring atomic-level precision, once reserved for small molecule ...

Demis Hassabis, a Nobel laureate for his AI research and the CEO of Google DeepMind, said on Sunday that he hopes that AI ...

GenAI offers a realistic path forward in tackling previously undruggable targets, with the potential to reshape the entire ...

Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...

Artificial intelligence-assisted drug discovery and design is a method that utilizes artificial intelligence (AI) technology to accelerate and optimize the drug development process. Traditional drug ...

Google DeepMind CEO Demis Hassabis envisions AI eradicating all diseases within a decade, potentially revolutionizing drug ...

The company is building what it describes as an AI drug design engine. The software reduces the amount of manual work involved in developing new medicines and thereby speeds up the process.

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

The AI-first drug design and development company plans to utilize the investment to advance its AI drug design engine, enhance software capabilities, finance drug development programs, and ...